2021 / 03

Next Paper
DOI: 10.24075/brsmu.2021.026

ORIGINAL RESEARCH

Changes in blood levels of IL1 family cytokines in patients with essential hypertension after having COVID-19

Radaeva OA1, Simbirtsev AS2, Kostina YuA1, Iskandiarova MS1, Mashnina SV1, Bessheynov DD, Negodnova EV1, Kulyapkin VV1
About authors

1 National Research Mordovia State University, Saransk, Russia

2 State Research Institute of Highly Pure Biopreparations, FMBA, St. Petersburg, Russia

Correspondence should be addressed: Olga A. Radaeva
Ulyanova, 26а, Saransk, 430020; ur.liam@demaveadar

About paper

Author contribution: Radaeva ОА — study design, analysis of the results, manuscript editing; Simbirtsev АS — formulating research aim, final version of the article; Kostina YuA — laboratory tests, manuscript editing; Iskandyarova МS — literature analysis, working on the first manuscript draft; Mashnina SV — literature analysis, monitoring of patients; Bessheynov DD — statistical data processing; Negodnova EV — working on the first manuscript draft; Kulyapkin VV — statistical processing of data obtained during the 6th month of follow-up.

Compliance with ethical standards: the study was approved by the Ethics Committee of the National Research Mordovia State University (protocol № 12 dated December 14, 2008, protocol № 85 dated May 27, 2020), the research was carried out in accordance with the WMA Declaration of Helsinki (2013) and the protocol of the Convention on Human Rights and Biomedicine (1999) taking into consideration the Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research (2005). Informed consent was submitted by all patients.

Received: 2021-05-19 Accepted: 2021-06-02 Published online: 2021-06-07
|
  1. Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020; 17 (11): 1984–90.
  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506.
  3. Alyammahi SK, Abdin SM, Alhamad DW, Elgendy SM, Altell AT, Omar HA. The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities. Infect Genet Evol. [Internet] 2021 [cited 2021 Mach 8]; 87: [about 1 p.]. Available from: https://www.sciencedirect.com/science/article/pii/ S1567134820304780?via%3Dihub.
  4. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016; 1 (3): 274–81.
  5. Brack MC, Lienau J, Kuebler WM, Witzenrath M. Cardiovascular sequelae of pneumonia. Curr Opin Pulm Med. 2019; 25 (3): 257–62.
  6. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015; 313 (3): 264–74.
  7. Richardson S, Hirsch JS, Narasimhan M. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323 (20): 2052–9.
  8. Korostovceva LS, Rotar OP, Konradi AO. Covid-19: kakovy riski pacientov s arterial'noj gipertenziej? AG. 2020; 26 (2): 124–32. Russian.
  9. Liu Y, Zhang HG. Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection. Front Med (Lausanne). [Internet] 2021 Jan [cited 2021 Apr 24] 20; 7: [about 1 p.]. Available from: https://jamanetwork.com/journals/jama/fullarticle/2091304.
  10. Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Complicaciones neurológicas por coronavirus y COVID-19. Rev Neurol. 2020; 70 (9): 311–22.
  11. Van de Veerdonk FL, Netea MG. Blocking IL1 to prevent respiratory failure in COVID-19. Crit Care. [Internet] 2020 Jul 18 [cited 2021 Apr 24]; 24 (1): [about 1 p.]. Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03166-0.
  12. Rowaiye AB, Okpalefe OA, Onuh Adejoke O, Ogidigo JO, Hannah Oladipo O, Ogu AC. Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. J Inflamm Res. 2021; 14: 1487–510.
  13. Radaeva OA. Citokiny v patogeneze i diagnostike jessencial'noj arterial'noj gipertenzii [dissertacija]. M., 2019. Russian.
  14. Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2019; 115 (4): 776–87.
  15. Savoia C, Volpe M, Kreutz R. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives. Circ Res. 2021; 128 (7): 1062–79.
  16. Siripanthong B, Nazarian S, Muser D. Recognizing COVID-19related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020; 17 (9): 1463–71.
  17. McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circ Res. 2015; 116 (6): 1022–33.
  18. Tain Y-L, Hsu C-N. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins. 2017; 9 (3): 92–97.
  19. Paish HL, Kalson NS, Smith GR, et al. Fibroblasts Promote Inflammation and Pain via IL1α Induction of the Monocyte Chemoattractant Chemokine (C-C Motif) Ligand 2. Am J Pathol. 2018; 188 (3): 696–714.
  20. Conti P, Lessiani G, Kritas SK, Ronconi G, Caraffa A, Theoharides TC. Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL37 inhibition. Tissue & Cell. 2017; 49 (3): 393–400.
  21. Radaeva OA, Simbircev AS. Analiz patogeneticheskih svjazej IL18, IL18BP, IL37 i vazoaktivnyh veshhestv (AT II, ET-1, NO, ADMA, SDMA, ENOS, INOS, NT-PROCNP i NT-PROBNP) pri jessencial'noj arterial'noj gipertenzii. Medicinskij vestnik Severnogo Kavkaza. 2019; 14 (1–2): 235–8.
  22. Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, et al. Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol. 2012; 303 (3): 282–96.
  23. OZzbiçer S, Ulucam ZM. Association between Interleukin-18 Level and Left Ventricular Mass Index in Hypertensive Patients. Korean Circulation Journal. 2017; 47 (2): 238–44.
  24. Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. [Internet] 2020 Dec 4 [cited 2021 Apr 24]; 5 (1): [about 1 p.]. Available from: https://www. nature.com/articles/s41392-020-00426-x.
  25. Venkatesan B, Valente AJ, Prabhu SD, Shanmugam P, Delafontaine P, Chandrasekar B. EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-κB and MKK7/JNK/AP-1 signaling. Journal of Molecular and Cellular Cardiology. 2010; 49 (4): 655–63.